Antibody immunosuppressive therapy in solid organ transplant: Part II

mAbs

Volumn 2, Issue 6, 2010, Pages 607-612

  Klipa, Dusko ^a   Mahmud, Nadim ^b   Ahsan, Nasimul ^c  

^a MAYO CLINIC   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Anti adhesion; Antibody; Biologics; Immunosuppression; Transplantation

Indexed keywords

ABATACEPT; ALEFACEPT; BASILIXIMAB; BELATACEPT; BELIMUMAB; CELL SURFACE RECEPTOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT RECEPTOR; CORTICOSTEROID; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACLIZUMAB; ECULIZUMAB; EFALIZUMAB; EPRATUZUMAB; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 2; INTERLEUKIN 6; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; P SELECTIN GLYCOPROTEIN LIGAND 1; QPI 1002; RAPAMYCIN; RITUXIMAB; SMALL INTERFERING RNA; TOCILIZUMAB; TP 10; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ANTIBODY MEDIATED REJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG MECHANISM; GRAFT REJECTION; HLA SYSTEM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; ISCHEMIA; KIDNEY TRANSPLANTATION; NONHUMAN; PLASMAPHERESIS; RANDOMIZED CONTROLLED TRIAL; REPERFUSION INJURY; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION;

EID: 78649657061     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.2.6.13586     Document Type: Review

References (41)

1. Mahmud N, Klipa D, Ahsan N. Antibody immunosuppressive therapy in solid organ transplant - part I. mAbs 2010; 2:148-56.
2. Larsen CP, Pearson TC, Adams AB, Tso P, Shirasugi N, Strobert E, at al. Rational development of LEA29Y (belatacept), a high affinity variant of CTLA4Ig with potent immunosuppressive properties. Am J Transplant 2005; 5:443-53.
3. Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, et al. A pIII Study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10:535-46.
4. Bluestone JA, Liu W, Yabu JM, Laszig ZG, Putnam A, Belingheri M, et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 2008; 10:2086-96.
5. Nicolls MR, Gill RG. LFA-1 (CD11a) as a therapeutic target. Am J Transplant 2006; 6:27-36.
6. Vincenti F, Mendez R, Pescovitz M, Rajagopalan PR, Wilkinson AH, Butt K. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant 2007; 7:1770-7.
7. United States Food and Drug Administration. http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsand Providers/ucm133337. htm. Accessed March 1 2010.
8. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. NEJM 2001; 345:248-55.
9. Weaver TA, Charafeddine AH, Agarwal A, Turner AP, Russell M, Leopardi FV. Alefacept promotes co-stimulation blockade based allograft survival in primates. Nat Med 2009; 15:746-9.
10. Astellas Pharma Inc., study NCT00543569. http://clinicaltrials.gov/ct2/ show/NCT00543569?term=alefacept&rank=21. Accessed September 12 2010.
11. Manthey HD, Woodruff TM, Taylor SM, Monk PN. Complement component 5a (C5a). Int J Biochem Cell Biol 2009; 41:2114-17.
12. Stegall MD, Dean PG, Gloor J. Mechanism of alloantibody production in sensitized renal allograft recipients. Am J Transplant 2009; 9:998-1005.
13. Stegall MD, Gloor JM. Deciphering antibody-mediated rejection: new insights into mechanisms and treatment. Curr Opin Organ Transplant 2010; 15:8-10.
14. Locke JE, Magro CM, Singer AL, Segev DL, Haas M, Hillel AT, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009; 9:231-5.
15. Henderson JM. Liver transplantation and rejection: an overview. Hepatogastroenterology 1999; 46:1482-4.
16. Morell CN, Sun H, Swain AM, Baldwin WM. Platelets an inflammatory force in transplantation. Am J Transplant 2007; 7:2447-54.
17. Garcia-Criado FJ, Toledo-Pereyra LH, Lopez-Neblina F, Phillips ML, Paez-Rollys A, Misawa K. Role of P-selectin in total hepatic ischemia and reperfusion. J Am Coll Surg 1995; 181:324-34.
18. Tsuchihashi S, Fondevila C, Shaw DG, Lorenz M, Marquette K, Benard S. Molecular characterization of rat leukocyte P-selectin glycoprotein ligand-1 and effect of its blockade: protection from ischemia-reperfusion injury in liver transplantation. J Immunol 2006; 176:616-24.
19. Li JS, Jaggers J, Anderson PA. The use of TP10, soluble complement receptor 1, in cardiopulmonary bypass. Expert Rev Cardiovasc Ther 2006; 4:649-54.
20. Bizzarri C, Beccari AR, Bertini R, Cavicchia MR, Giorgini S, Allegretti M. ELR + CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets. Pharmacol Ther 2006; 112:139-49.
21. Cugini D, Azzollini N, Gagliardini E, Cassis P, Bertini R, Colotta F. Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion. Kidney Int 2005; 67:1753-61.
22. Quark Pharmaceuticals http://quarkpharma.com/qbien/products/qpi-1002. Accessed September 12 2010.
23. Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004; 4:996-1001.
24. Genberg H, Kumlien G, Wennberg L, Berg U, Tydén G. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up. Transplantation 2004; 85:996-1001.
25. Tydén G, Genberg H, Tollemar J, Ekberg H, Persson NH, Tufveson G. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation 2009; 87:1325-9.
26. Clatworthy MR, Watson CJ, Plotnek G, Bardsley V, Chaudhry AN, Bradley JA, et al. B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med 2009; 360:2683-5.
27. Kamar N, Milioto O, Puissant-Lubrano B, Esposito L, Pierre MC, Mohamed AO, et al. Incidence and predictive factors for infectious diseases after rituximab therapy in kidney transplant patients. Am J Transplant 2010; 10:89-98.
28. Shelton E, Yong M, Cohney S. Late onset Pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection. Nephrology 2009; 14:696-9.
29. Bitzan M, Ouahed JD, Carpineta L, Bernard C, Bell LE. Cryptogenic organizing pneumomnia after rituximab therapy for presumed post-kidney transplant lymphoproliferative disease. Pediatr Nephrol 2010; 25:1163-7.
30. Kamar N, Mengelle C, Rostaing L. Incidence of JC-virus replication after rituximab therapy in solid-organ transplant patients. Am J Transplant 2009; 9:244-5.
31. Vincenti F, Kirk AD. What's next in the pipeline. Am J Transplant 2008; 8:1972-81.
32. Do RK, Hatada E, Lee H, Tourigny MR, Hilbert D, Chen-Kiang S. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med 2000; 192:953-64.
33. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008; 58:2968-80.
34. Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther 2006; 2:2.
35. Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997; 6:315-25.
36. Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, et al. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001; 14:705-14.
37. Karczewski M, Karczewski J, Poniedzialek B, Wiktorowicz K, Smietanska M, Glyda M. Distinct cytokine patterns in different states of kidney allograft function. Transplant Proc 2009; 41:4147-9.
38. Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301:418-26.
39. Baert FJ, D'Haens GR, Peeters M, Hiele MI, Shaible TF, Shealy D, et al. Tumor necrosis factor-α antibody (infliximab) therapy profoundly downregulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999; 116:22-8.
40. Di Sabatino A, Ciccocioppo R, Cinque B, Millimaggi D, Morera R, Ricevuti L, et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 2004; 53:70-7.
41. Hribova P, Kotsch K, Brabcova I, Vitko S, Volk HD, Lacha J. Cytokines and chemokine gene expression in human kidney transplantation. Transplant Proc 2005; 37:760-3. (Pubitemid 40590692)